Toxicity

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Health, Longevity, Drug discovery, Science, Media, Partnership, Education, Patient, Research, Security (finance), Investigational New Drug, OTC, Catalog, Immune system, International Cannabinoid Research Society, Nursing, Pharmaceutical industry

Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.

Key Points: 
  • Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.
  • In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field.
  • GenBio has reviewed numerous natural extracts over the last five years.
  • GenBio’s current research program is a potentially powerful anti-inflammatory drug program with lower toxicity than existing pharmaceutical drugs.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Concept, Plasma, Candidate, RECIST, Oncology, RAS, Patient, FACP, City, Cancer, Pancreatic cancer, Neoplasm, Therapy, Safety, Pharmacokinetics, SLD, Pharmaceutical industry

“Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Key Points: 
  • “Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.
  • Immuneering evaluated both 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study.
  • The Phase 2a portion is expected to include up to twenty clinical sites and has already dosed its first patient.
  • Initial data from multiple arms of the Phase 2a portion of Immuneering’s Phase 1/2a study of IMM-1-104 expected in 2024.

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Notifiable disease, TELO, Entrepreneurship, Science, Research, DNA, Ageing, MD, Quality of life, Drug development, Osteoarthritis, Pharmaceutical industry

Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.

Key Points: 
  • Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
  • Additional AI-driven studies now being conducted to demonstrate Telomir-1's promising therapeutic potential, supporting Telomir’s hypothesis with solid computational evidence.
  • As part of its work, Telomir works with third-party collaborators Frontage Laboratories and InSilicoTrials, each of whom utilize AI in-silico testing models.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

TruEra Launches LLM Evaluation and Observability that Combines Leading Open Source Software and Massive Enterprise Scale

Retrieved on: 
Wednesday, March 13, 2024
Toxicity, UX, Organization, Software as a service, Entrepreneurship, Blog, AI, LLM, Architecture, Hallucination, KBC Group, Gen, UI, Equinix, Medical device

With these enhancements, TruEra becomes the only company with both a leading open source offering for LLM application evaluation and a scalable, enterprise-class evaluation and observability solution for both Generative and Predictive AI.

Key Points: 
  • With these enhancements, TruEra becomes the only company with both a leading open source offering for LLM application evaluation and a scalable, enterprise-class evaluation and observability solution for both Generative and Predictive AI.
  • TruEra’s open source solution, TruLens, provides LLM evaluation and tracking for the individual developer.
  • The latest release of TruEra AI Observability brings full Generative AI Observability and LLM Observability capabilities to teams, mid-size organizations, and the enterprise.
  • Learn how to get started and dive deep into the new capabilities in this blog, “ LLM Evaluation and LLM Observability - Now at Enterprise Scale .”

PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors

Retrieved on: 
Friday, April 5, 2024
Oncology, Medical Devices, Health, Surgery, Clinical Trials, Biotechnology, Boston University, Toxicity, Hematology, Genetics, Executive, Monoclonal antibody, Shire (pharmaceutical company), Merck, Acquisition, BMS, Cancer, University, Doctor of Philosophy, Panther, MBA, Marketing, Neoplasm, Therapy, Chemical engineering, Genetics Institute, F-star, FDA, Pharmaceutical industry

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.

Key Points: 
  • PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
  • “John has been an outstanding addition to our Board and management team since joining the company in September.
  • His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
  • During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.

Innovations in Small Molecule Drug Delivery and Formulation, 2024 Research Report - Collaborating with CDMOs to Intensify R&D Activities - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Molecule, Nanocarriers, Exosome, Toxicity, Solubility, Cancer, Ligand, Generic drug

The "Innovations in Small Molecule Drug Delivery and Formulation" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations in Small Molecule Drug Delivery and Formulation" report has been added to ResearchAndMarkets.com's offering.
  • Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy.
  • While the small molecule drug development pipeline remains a leading therapeutic class, it is essential to intensify R&D to improve drug delivery approaches.
  • This analysis of the latest advances in small molecule drug delivery covers developments in organic, inorganic, and carrier-free small molecule drug delivery systems (DDSs) as well as developments in formulations for improved patient adherence and targeted small molecule delivery.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Retrieved on: 
Wednesday, April 3, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Toxicity, Combination therapy, SOC, Survival, Disease, Patient, GBM, Vaccine, Neoplasm, Decompression (diving), Safety, VBI, Pharmaceutical industry

The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.

Key Points: 
  • The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.
  • Dr. Anderson commented: “In recurrent GBM, tumors typically double or triple in size within six weeks, with no effective treatments available to improve survival.
  • Early indications from this ongoing study suggest tumor growth behavior in-line with expectations for both the standard-of-care arm and the VBI-1901 arm, based on positive data seen from the Phase 1/2a study.
  • As of March 22, 2024, 17 patients have been randomized 1:1 to either the active, VBI-1901 treatment arm, or to the control, standard-of-care treatment arm (SoC).